Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis
Authors
Keywords
-
Journal
OncoImmunology
Volume 4, Issue 6, Pages e1008342
Publisher
Informa UK Limited
Online
2015-05-23
DOI
10.1080/2162402x.2015.1008342
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The immune contexture of primary and metastatic human tumours
- (2014) Nicolas A Giraldo et al. CURRENT OPINION IN IMMUNOLOGY
- slanDCs selectively accumulate in carcinoma-draining lymph nodes and marginate metastatic cells
- (2014) William Vermi et al. Nature Communications
- slanDCs in carcinoma-draining lymph nodes
- (2014) William Vermi et al. OncoImmunology
- Fc RIII (CD16) equips immature 6-sulfo LacNAc-expressing dendritic cells (slanDCs) with a unique capacity to handle IgG-complexed antigens
- (2013) T. Dobel et al. BLOOD
- Characteristics and Clinical Impacts of the Immune Environments in Colorectal and Renal Cell Carcinoma Lung Metastases: Influence of Tumor Origin
- (2013) R. Remark et al. CLINICAL CANCER RESEARCH
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- The expression, function, and clinical relevance of B7 family members in cancer
- (2012) Barbara Seliger et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Human 6-sulfo LacNAc (slan) dendritic cells have molecular and functional features of an important pro-inflammatory cell type in lupus erythematosus
- (2012) Anja Hänsel et al. JOURNAL OF AUTOIMMUNITY
- Human Renal Cell Carcinoma Induces a Dendritic Cell Subset That Uses T-Cell Crosstalk for Tumor-Permissive Milieu Alterations
- (2011) Ainhoa-M. Figel et al. AMERICAN JOURNAL OF PATHOLOGY
- Prognostic significance of CD45RO+ memory T cells in renal cell carcinoma
- (2011) K Hotta et al. BRITISH JOURNAL OF CANCER
- The Epidemiology of Renal Cell Carcinoma
- (2011) Börje Ljungberg et al. EUROPEAN UROLOGY
- Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong Th17/Th1 T-cell responses
- (2011) Anja Hänsel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The Bidirectional Crosstalk between Human Dendritic Cells and Natural Killer Cells
- (2011) Rebekka Wehner et al. Journal of Innate Immunity
- Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma
- (2010) Peter Middel et al. BMC CANCER
- Macrophage Diversity Enhances Tumor Progression and Metastasis
- (2010) Bin-Zhi Qian et al. CELL
- The dendritic cell–tumor cross-talk in cancer
- (2010) Yuting Ma et al. CURRENT OPINION IN IMMUNOLOGY
- EAU Guidelines on Renal Cell Carcinoma: The 2010 Update
- (2010) Börje Ljungberg et al. EUROPEAN UROLOGY
- Immune Regulation of Cancer
- (2010) Mary L. Disis JOURNAL OF CLINICAL ONCOLOGY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer
- (2009) Franck Pagès et al. JOURNAL OF CLINICAL ONCOLOGY
- Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma
- (2009) Christiane Geiger et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- Reciprocal activating interaction between 6-sulfo LacNAc+dendritic cells and NK cells
- (2008) Rebekka Wehner et al. INTERNATIONAL JOURNAL OF CANCER
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started